Healthcare & Life Sciences

Allosteros Therapeutics, Inc.

United States
Sign in to unlock

About

Allosteros Therapeutics, Inc. developed selective small-molecule inhibitors targeting the Ca2+-dependent kinase CaMKII, demonstrating preclinical efficacy for treating atrial fibrillation, ventricular arrhythmia, and heart failure by normalizing calcium homeostasis.

Explore Allosteros Therapeutics, Inc.'s full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.

Sign in to unlockView pricing